Cel Sci Corp

CVM

Exchange: NYSE
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0000725363

SEC filings (opens in a new tab)

In the last 90 days, Cel Sci Corp insiders filed 1 open-market purchase and 0 sales; 40 institutions reported holding it in 13F filings for Q2 2026, worth $2.08M in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding Cel Sci Corp changed between Q4 2025 and Q1 2026.

All holders in Q1 2026 All holders in Q4 2025

13F holders of CVM: Q4 2025 compared with Q1 2026
Measure	Q4 2025	Of which not filed for Q1 2026	Q1 2026	Change
Holders	40	1	39	0
Shares	742.2K	285.1K	762.7K	+305.6K (+66.9%)
Value	$3.90M	$1.50M	$2.43M	+$23.3K (+1.0%)

1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Cel Sci Corp at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to CVM in Q1 2026
Institution	Shares	Value	% of portfolio
Vanguard Capital Management LLC	243,645	$782.1K	0.00%
Vanguard Fiduciary Trust Co	49,036	$157.4K	0.00%
Forthright Family Wealth Advisory LLC	16,500	$31.5K	0.02%
Vanguard Global Advisers, LLC	536	$1.72K	0.00%
Advisory Services Network, LLC	9	$29	0.00%
Frazier Financial Advisors, LLC	3	$10	0.00%

Sold out (6)

Institutions that held Cel Sci Corp at the end of Q4 2025 and filed for Q1 2026 without it.

Institutions that sold out of CVM in Q1 2026
Institution	Shares, Q4 2025	Value, Q4 2025
Jane Street Group, LLC	15,707	$82.6K
Citadel Advisors LLC	11,806	$62.1K
HRT Financial LP	11,538	$60.0K
Fortitude Family Office, LLC	75	$395
SageView Advisory Group, LLC	6	$32
Navalign, LLC	3	$16

Not filed for Q1 2026 yet (1)

Institutions that held Cel Sci Corp at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding CVM in Q4 2025 that haven't filed for Q1 2026
Institution	Shares, Q4 2025	Value, Q4 2025
Vanguard Group Inc	285,117	$1.50M